PharmaJet Receives $9.6 Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices

PharmaJet has announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA).

DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices.

The initial studies underway are focused on delivery of Venezuelan Equine Encephalitis Virus (VEEV) DNA Vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the PharmaJet systems.

Chris Cappello, President and Chief Executive Officer, PharmaJet Inc. said, “we are excited to be collaborating with the U.S. Government to progress their vaccine development and next generation needle-free devices, which could include variable dose devices for additional pathogens. Our systems are already being used extensively in the field due to their ease-of-use, minimal training requirements and fast administration time.”

Novel High-Density Microarray Patch Can Deliver Vaccines Directly to the Skin

Regeneron Makes Progress on Novel COVID-19 Antibody Program